Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Suicidal ideation with and without intention to act, A transdiagnostic network analysis on the interplay between psychopathology, impulsivity, and childhood maltreatment

  • De Prisco, Michele|||0000-0002-2032-1181
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Canosa García, Irene
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Curto-Ramos, Javier
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Elices, M.|||0000-0002-7034-4242
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Palao, Diego|||0000-0002-3323-6568
  • Pemau, Andrés|||0000-0002-5835-507X
  • Lopez-Pena, Maria Purificacion
  • Ruiz Veguilla, Miguel
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Courtet, Philippe|||0000-0002-6519-8586
  • Vieta, Eduard|||0000-0002-0548-0053
  • Grande, Iria|||0000-0002-0137-0666
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Suicide represents a significant public health concern. Suicide prevention strategies are shifting toward transdiagnostic perspectives examining interrelated risk factors, but their interrelationships remain unclear. This study investigated relationships between psychopathological dimensions, impulsivity, and childhood maltreatment in individuals with suicidal ideation (SI), comparing those with versus without intention to act using network analysis. Data were obtained from the Suicide Prevention and Intervention Study project. Participants were categorized into two groups based on their intention to act according to the Columbia Suicide Severity Rating Scale. Psychological symptoms, impulsivity traits, and childhood maltreatment were assessed. Network analysis was performed, and centrality measures were computed. A total of 1,265 individuals were categorized into the SI without intention to act (n = 345) and SI with intention to act (n = 920) groups. The former showed lower depression and hostility scores, and lower prevalence of major depressive and anxiety disorders. Network analyses revealed that in the SI without intention to act group, obsessive-compulsive symptoms were central, connecting to depression and anxiety, while negatively correlating with non-planning impulsivity. In contrast, the SI with intention to act group showed a more densely interconnected network where emotional abuse served as a bridge between childhood maltreatment and other psychopathological dimensions. This study identifies symptom interaction patterns between individuals with SI without and with intention to act. Understanding these relationships may improve suicide risk assessment and inform personalized interventions, potentially reducing the transition from ideation to action. Trauma-focused approaches addressing emotional abuse may be especially relevant for individuals at high risk.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Biomarkers of treatment-resistant schizophrenia: A systematic review

  • Pisanu, Claudia
  • Severino, Giovanni
  • Minelli, Alessandra
  • Dierssen, Mara
  • Potier, Marie-Claude
  • Fabbri, Chiara
  • Serretti, Alessandro
  • Gennarelli, Massimo
  • European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network
  • Baune, Bernhard T.
  • Squassina, Alessio
Treatment-resistant schizophrenia (TRS) is associated with great disability, functional impairment, and substantial socioeconomic costs. While clozapine is indicated in patients with TRS, its use is restricted to patients who have not responded to at least 2 other antipsychotics, thus implying a series of empirical trials of different drugs before receiving effective treatment. In this scenario, the identification of reliable biological markers to predict the risk for TRS before starting pharmacological treatments might significantly improve the management of TRS in its early stages. We conducted a systematic review on PubMed, Scopus and Web of Science to identify studies investigating peripheral biological markers of TRS. A total of 75 articles were included. These studies mostly investigated the association between TRS and genetic markers (n = 42, of which 16 with a genome-wide and 25 with a candidate-gene design) and protein/metabolite markers (n = 23), while only a minority of studies investigated RNA markers (n = 5), methylation levels (n = 4), gut microbiota profiles (n = 1), or more than one type of marker (n = 3). The elucidation of peripheral biomarkers of TRS is challenging due to the large heterogeneity across studies in terms of clinical definition of TRS, the relatively small sample size of many studies, as well as the lack of powered studies integrating data at a multi-omic level. Nonetheless, available studies suggest TRS to be a trait with a significant heritability and point to inflammation and cytokine imbalance as the most promising pathways involved in this complex phenotype., Bernhard T Baune, Claudia Pisanu, Mara Dierssen, Marie-Claude Potier, Chiara Fabbri, Alessandro Serretti, Alessio Squassina and Alessandra Minelli received support from Psych-STRATA, a project funded from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057454. Massimo Gennarelli received support by the Italian Ministry of Health under Grant [Ricerca Corrente 2022].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe

  • Baune, Bernhard T.
  • Dierssen, Mara
  • Ziller, Jacques
Schizophrenia (SCZ), bipolar (BD) and major depression disorder (MDD) are severe psychiatric disorders that are challenging to treat, often leading to treatment resistance (TR). It is crucial to develop effective methods to identify and treat patients at risk of TR at an early stage in a personalized manner, considering their biological basis, their clinical and psychosocial characteristics. Effective translation of theoretical knowledge into clinical practice is essential for achieving this goal. The Psych-STRATA consortium addresses this research gap through a seven-step approach. First, transdiagnostic biosignatures of SCZ, BD and MDD are identified by GWAS and multi-modal omics signatures associated with treatment outcome and TR (steps 1 and 2). In a next step (step 3), a randomized controlled intervention study is conducted to test the efficacy and safety of an early intensified pharmacological treatment. Following this RCT, a combined clinical and omics-based algorithm will be developed to estimate the risk for TR. This algorithm-based tool will be designed for early detection and management of TR (step 4). This algorithm will then be implemented into a framework of shared treatment decision-making with a novel mental health board (step 5). The final focus of the project is based on patient empowerment, dissemination and education (step 6) as well as the development of a software for fast, effective and individualized treatment decisions (step 7). The project has the potential to change the current trial and error treatment approach towards an evidence-based individualized treatment setting that takes TR risk into account at an early stage., The Psych-STRATA project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057454. BTB received funding from the German Federal Ministry of Health (BMG) [2521FSB004_PROMPT, ERAPERMED2020] and La Marato TV3: SLD044/20/000001 (Convocatoria ERAPERMED2020). MD received funding from PROMPT and La Marato TV3: SLD044/20/000001 (Convocatoria ERAPERMED2020) + Amb el suport del Departament de Salut, Fundació La Marató de TV3, 202212-30. AHY independent research is funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author Manuscript version arising from this submission. M-CP was supported with funding from the Investissement d’Avenir (ANR-10-AIHU-06).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis

  • Pistis, Giorgio
  • Vázquez-Bourgon, Javier
  • Fournier, Margot
  • Jenni, Raoul
  • Cleusix, Martine
  • Papiol, Sergi
  • Smart, Sophie E.
  • Pardiñas, Antonio F.
  • Walters, James T. R.
  • MacCabe, James H.
  • Kutalik, Zoltán
  • Conus, Philippe
  • Crespo-Facorro, Benedicto
  • Do, Kim Q.
Polygenic risk prediction remains an important aim of genetic association studies. Currently, the predictive power of schizophrenia polygenic risk scores (PRSs) is not large enough to allow highly accurate discrimination between cases and controls and thus is not adequate for clinical integration. Since PRSs are rarely used to reveal biological functions or to validate candidate pathways, to fill this gap, we investigated whether their predictive ability could be improved by building genome-wide (GW-PRSs) and pathway-specific PRSs, using distance- or expression quantitative trait loci (eQTLs)- based mapping between genetic variants and genes. We focused on five pathways (glutamate, oxidative stress, GABA/interneurons, neuroimmune/neuroinflammation and myelin) which belong to a critical hub of schizophrenia pathophysiology, centred on redox dysregulation/oxidative stress. Analyses were first performed in the Lausanne Treatment and Early Intervention in Psychosis Program (TIPP) study (n = 340, cases/controls: 208/132), a sample of first-episode of psychosis patients and matched controls, and then validated in an independent study, the epidemiological and longitudinal intervention program of First-Episode Psychosis in Cantabria (PAFIP) (n = 352, 224/128). Our results highlighted two main findings. First, GW-PRSs for schizophrenia were significantly associated with early psychosis status. Second, oxidative stress was the only significantly associated pathway that showed an enrichment in both the TIPP (p = 0.03) and PAFIP samples (p = 0.002), and exclusively when gene-variant linking was done using eQTLs. The results suggest that the predictive accuracy of polygenic risk scores could be improved with the inclusion of information from functional annotations, and through a focus on specific pathways, emphasizing the need to build and study functionally informed risk scores., National Center of Competence in Research (NCCR) “SYNAPSY-The Synaptic Bases of Mental Diseases” from the Swiss National Science Foundation (n°51AU40_125759 to KQD & PC), and Alamaya Foundation. SP was supported by European Union’s Horizon 2020 Research and Innovation Program (Psych-STRATA). The PAFIP cohort was funded by the following grants (to BC-F): Instituto de Salud Carlos III (FIS00/3095, PI020499, PI050427, PI060507), Plan Nacional de Drogas Research (2005-Orden sco/3246/2004), SENY Fundatio Research (2005-0308007), Fundacion Marques de Valdecilla (A/02/07, API07/011) and MINECO/FEDER (SAF2016-76046-R, SAF2013-46292-R). JV-B was supported by Instituto de Investigación Sanitaria Valdecilla (INT/A21/10, INT/A20/04). Open access funding provided by University of Lausanne., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort

  • De Prisco, Michele
  • Oliva, Vincenzo
  • Sanchez-Valle, Raquel
  • Parellada, Eduard
  • Junque, Carme
  • Marti, Maria J.
  • Bortolozzi, Analía
  • Alberch, Jordi
  • Garrabou, Gloria
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Segura, Barbara
  • Lladó, Albert
  • Compta, Yaroslau
  • Radua, Joaquim
  • Vieta, Eduard
  • Hidalgo-Mazzei, Diego
  • Anmella, Gerard
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. Dementia and ischemic stroke contribute substantially to this burden, yet age-specific patterns of these associations remain poorly characterized. To bridge this gap, we conducted a population-based cross-sectional study using the PADRIS-PRESTO cohort, integrating primary and specialized care records from the Catalan public health system (Spain). Adults with a lifetime SMI diagnosis were compared with controls without any psychiatric condition. Weighted age-stratified prevalence was calculated and logistic regression models estimated age-specific odds ratios (ORs) with 95% confidence intervals (CIs), adjusting for socioeconomic status and medical comorbidity burden. Among 694,086 participants, 176,870 had an SMI diagnosis. Dementia prevalence was 3.49% (range, 0.33% at ages 20-29 to 39.51% at 90-99 years) in SMIs and 0.36% (0.02%-17.7%) in controls. Ischemic stroke prevalence was 5.3% (0.22%-16.4%) in SMIs and 2.75% (0.08%-14.67%) in controls. The ORs between SMI and dementia were significant across all age groups, with the strongest association observed at younger ages (OR = 23.21, 95% CIs = 13.74-39.19 at 30-39 years). Elevated ORs for stroke persisted up to 70-79 years, peaking at 40-49 years (OR = 2.99, 95% CIs = 2.63-3.41). Patterns were consistent across SMI subtypes. These findings highlight the need for earlier and more systematic neurological and cardiometabolic screening and management within psychiatric care and support policies that recognize SMIs as risk factors for vascular diseases and dementia., Michele De Prisco is supported by the Translational Research Programme for Brain Disorders, IDIBAPS. Vincenzo Oliva thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (CM24/00143, MV25/00042). Carme Junque thanks the Spanish Ministry of Economy and Competitiveness (MINECO PID2020-114640GB-I00/ and PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Analia Bortolozzi thanks the Spanish Ministry of Economy and Competitiveness (MCIU/AEI/FEDER, UE grant PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033); La Marató de TV3 Foundation 202207-30; and Caixa Research Health - HR25-00556. Jordi Alberch is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2024-157024OB-I00). Gloria Garrabou is supported by The Catalan Government (2021-SGR-01423), and Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (PI24/00428) and CIBERER, both initiatives of ISCIII and FEDER, co-funded by the European Union. Maria V. Sanchez-Vives is funded by the European Union (ERC, NEMESIS, project number 101071900). Albert Giralt is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2020-119386RB-I00). Barbara Segura thanks the Spanish Ministry of Economy and Competitiveness (PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Joaquim Radua thanks the support of the Spanish Ministry of Science, Innovation and Universities (CPII19/00009, PI22/00261, PI25/01463) integrated into the Plan Nacional de I + D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and the Instituto de Salud Carlos III; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021-SGR-01128). Eduard Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432) integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project). Diego Hidalgo-Mazzei gratefully acknowledges the support of the Spanish Ministry of Health, Instituto de Salud Carlos III (PI049759) and the Pons-Bartran Legacy grant 2024 (FCRB_IPB1_2024). Gerard Anmella thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI24/00584, PI24/01051, PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) - Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM); and the Translational Research Programme for Brain Disorders, IDIBAPS. IG has received support from the Spanish Ministry of Science, Innovation and Universities (MCIN) (PI23/00822) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and European Union (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme / Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Can Polygenic Risk Scores for Metabolic Syndrome Contribute to Long-Term Syndrome Development in First-Episode Psychosis Patients? A Naturalistic 21-Year Follow-Up Study

  • Cuesta, Manuel Jesús
  • Papiol, Sergi
  • Giné-Servén, Eloi
  • Ballesteros, Alejandro
  • Gil-Berrozpe, Gustavo J
  • Peralta, David
  • Crespo-Facorro, Benedicto
  • Sánchez-Torres, Ana M
  • Peralta, Víctor
  • Ansorena, Xabier
  • Chato, Julen
  • Fañanás, Lourdes
  • García de Jalón, Elena
  • Janda, Lucía
  • Moreno-Izco, Lucía
  • Ribeiro, María
  • Rosado, Esther
  • Rosero, Angela
[Background and Hypothesis] Metabolic syndrome (MetS) is still a challenge for clinicians treating patients with first-episode psychosis (FEP)., [Study Design] We explored whether polygenic risk scores for MetS (PRSMetS) may be associated with MetS in FEP patients. The sample comprised 164 FEP patients who were followed-up for a mean of 20.9 years. MetS was defined according to the ATP III criteria at the end of the follow-up. We used logistic regression models to examine the contribution of PRSs for the development of MetS and associated metabolic symptoms after allowing for the effect of covariates. Furthermore, we investigated the relationships between PRSMetS and metabolic symptoms using network analysis (NA)., [Study Results] PRSMetS significantly contributed to the development of MetS and the increase of waist circumference at the long-term follow-up, accounting for 7.9% and 6.8% of the explained variance, respectively. Moreover, the PRS of high-density lipoprotein cholesterol levels showed a significant association value for hypertension, accounting for 5.6% of the variance., PRSMetS showed a significant linear trend with the number of MetS criteria and this trend remained significant after allowing for standard epidemiological and clinical baseline variables in the hierarchical multiple regression analysis. PRSMetS, PRSWaist, and the five metabolic criteria showed rich interconnections in the network analysis., [Conclusions] MetS PRSs showed significant relationships with metabolic disturbances in patients with FEP over a lifetime. Our findings may offer promising avenues for the PRSMetS to be integrated with relevant clinical measures for identifying the FEP patients most vulnerable to develop MetS., This study was funded by the Government of Navarra (grants 17/31 and 18/41) and the Carlos III Health Institute (FEDER Funds) from the Spanish Ministry of Economy and Competitiveness (PI16/02148, PI19/01698, RD21/0009/0025 and RD24/0003/0015). S.P. was supported by the Psych-STRATA project from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057454., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe

  • Baune, Bernhard T.
  • Dierssen, Mara
  • Ziller, Jacques
Schizophrenia (SCZ), bipolar (BD) and major depression disorder (MDD) are severe psychiatric disorders that are challenging to treat, often leading to treatment resistance (TR). It is crucial to develop effective methods to identify and treat patients at risk of TR at an early stage in a personalized manner, considering their biological basis, their clinical and psychosocial characteristics. Effective translation of theoretical knowledge into clinical practice is essential for achieving this goal. The Psych-STRATA consortium addresses this research gap through a seven-step approach. First, transdiagnostic biosignatures of SCZ, BD and MDD are identified by GWAS and multi-modal omics signatures associated with treatment outcome and TR (steps 1 and 2). In a next step (step 3), a randomized controlled intervention study is conducted to test the efficacy and safety of an early intensified pharmacological treatment. Following this RCT, a combined clinical and omics-based algorithm will be developed to estimate the risk for TR. This algorithm-based tool will be designed for early detection and management of TR (step 4). This algorithm will then be implemented into a framework of shared treatment decision-making with a novel mental health board (step 5). The final focus of the project is based on patient empowerment, dissemination and education (step 6) as well as the development of a software for fast, effective and individualized treatment decisions (step 7). The project has the potential to change the current trial and error treatment approach towards an evidence-based individualized treatment setting that takes TR risk into account at an early stage., The Psych-STRATA project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057454. BTB received funding from the German Federal Ministry of Health (BMG) [2521FSB004_PROMPT, ERAPERMED2020] and La Marato TV3: SLD044/20/000001 (Convocatoria ERAPERMED2020). MD received funding from PROMPT and La Marato TV3: SLD044/20/000001 (Convocatoria ERAPERMED2020) + Amb el suport del Departament de Salut, Fundació La Marató de TV3, 202212-30. AHY independent research is funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author Manuscript version arising from this submission. M-CP was supported with funding from the Investissement d’Avenir (ANR-10-AIHU-06).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Biomarkers of treatment-resistant schizophrenia: A systematic review

  • Pisanu, Claudia
  • Severino, Giovanni
  • Minelli, Alessandra
  • Dierssen, Mara
  • Potier, Marie-Claude
  • Fabbri, Chiara
  • Serretti, Alessandro
  • Gennarelli, Massimo
  • European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network
  • Baune, Bernhard T.
  • Squassina, Alessio
Treatment-resistant schizophrenia (TRS) is associated with great disability, functional impairment, and substantial socioeconomic costs. While clozapine is indicated in patients with TRS, its use is restricted to patients who have not responded to at least 2 other antipsychotics, thus implying a series of empirical trials of different drugs before receiving effective treatment. In this scenario, the identification of reliable biological markers to predict the risk for TRS before starting pharmacological treatments might significantly improve the management of TRS in its early stages. We conducted a systematic review on PubMed, Scopus and Web of Science to identify studies investigating peripheral biological markers of TRS. A total of 75 articles were included. These studies mostly investigated the association between TRS and genetic markers (n = 42, of which 16 with a genome-wide and 25 with a candidate-gene design) and protein/metabolite markers (n = 23), while only a minority of studies investigated RNA markers (n = 5), methylation levels (n = 4), gut microbiota profiles (n = 1), or more than one type of marker (n = 3). The elucidation of peripheral biomarkers of TRS is challenging due to the large heterogeneity across studies in terms of clinical definition of TRS, the relatively small sample size of many studies, as well as the lack of powered studies integrating data at a multi-omic level. Nonetheless, available studies suggest TRS to be a trait with a significant heritability and point to inflammation and cytokine imbalance as the most promising pathways involved in this complex phenotype., Bernhard T Baune, Claudia Pisanu, Mara Dierssen, Marie-Claude Potier, Chiara Fabbri, Alessandro Serretti, Alessio Squassina and Alessandra Minelli received support from Psych-STRATA, a project funded from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057454. Massimo Gennarelli received support by the Italian Ministry of Health under Grant [Ricerca Corrente 2022].
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Can polygenic risk scores for metabolic syndrome contribute to long-term syndrome development in first-episode psychosis patients?: a naturalistic 21-year follow-up study

  • Cuesta, Manuel J.
  • Papiol, Sergi
  • Giné-Servén, Eloi
  • Ballesteros, Alejandro
  • Gil Berrozpe, Gustavo José
  • Peralta, David
  • Crespo-Facorro, Benedicto
  • Sánchez Torres, Ana María
  • Peralta Martín, Víctor
  • SEGPEPs Group
Background and Hypothesis Metabolic syndrome (MetS) is still a challenge for clinicians treating patients with first-episode psychosis (FEP).Study Design We explored whether polygenic risk scores for MetS (PRSMetS) may be associated with MetS in FEP patients. The sample comprised 164 FEP patients who were followed-up for a mean of 20.9 years. MetS was defined according to the ATP III criteria at the end of the follow-up. We used logistic regression models to examine the contribution of PRSs for the development of MetS and associated metabolic symptoms after allowing for the effect of covariates. Furthermore, we investigated the relationships between PRSMetS and metabolic symptoms using network analysis (NA).Study Results PRSMetS significantly contributed to the development of MetS and the increase of waist circumference at the long-term follow-up, accounting for 7.9% and 6.8% of the explained variance, respectively. Moreover, the PRS of high-density lipoprotein cholesterol levels showed a significant association value for hypertension, accounting for 5.6% of the variance. PRSMetS showed a significant linear trend with the number of MetS criteria and this trend remained significant after allowing for standard epidemiological and clinical baseline variables in the hierarchical multiple regression analysis. PRSMetS, PRSWaist, and the five metabolic criteria showed rich interconnections in the network analysis.Study Results PRSMetS significantly contributed to the development of MetS and the increase of waist circumference at the long-term follow-up, accounting for 7.9% and 6.8% of the explained variance, respectively. Moreover, the PRS of high-density lipoprotein cholesterol levels showed a significant association value for hypertension, accounting for 5.6% of the variance. PRSMetS showed a significant linear trend with the number of MetS criteria and this trend remained significant after allowing for standard epidemiological and clinical baseline variables in the hierarchical multiple regression analysis. PRSMetS, PRSWaist, and the five metabolic criteria showed rich interconnections in the network analysis.Conclusions MetS PRSs showed significant relationships with metabolic disturbances in patients with FEP over a lifetime. Our findings may offer promising avenues for the PRSMetS to be integrated with relevant clinical measures for identifying the FEP patients most vulnerable to develop MetS., This study was funded by the Government of Navarra (grants 17/31 and 18/41) and the Carlos III Health Institute (FEDER Funds) from the Spanish Ministry of Economy and Competitiveness (PI16/02148, PI19/01698, RD21/0009/0025 and RD24/0003/0015). S.P. was supported by the Psych-STRATA project from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057454.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Polygenic risk score for neurodevelopmental disorders and cognitive impairment at long-term follow-up of first-episode psychosis

  • Cuesta, Manuel J.
  • Papiol, Sergi
  • Gil Berrozpe, Gustavo José
  • Giné-Servén, Eloi
  • Ballesteros, Alejandro
  • Peralta, David
  • Sánchez Torres, Ana María
  • García de Jalón, Elena
  • Peralta Martín, Víctor
  • SEGPEPs Group
Background: One of the most outstanding contributions to the understanding of the etiopathogenesis of schizophrenia spectrum disorders (SSD) was the neurodevelopmental hypothesis. SSD and neurodevelopmental disorders (NDD) share pathogenetic mechanisms and overlapping clinical and cognitive impairment features. Methods: We investigated whether polygenic risk scores (PRSs) for NDD are associated with cognitive performance in patients with first-episode psychosis (FEP). The sample comprised 127 patients with FEP who were followed up for a mean of 20.9 years. Cognitive examination was performed using the MoCA test at follow-up. Pearson coefficient correlations and multiple regression analyses were performed to examine the contribution of the three PRSs for rare neurodevelopmental conditions (PRSNDD), attention-deficit hyperactivity disorder (PRSADHD) and autism spectrum disorder (PRSASD) to cognitive impairment after allowing for the effect of covariates. Furthermore, we examined the interconnections between the PRS for NDD and cognitive impairment using network analysis (NA), including core premorbid variables. Results: PRSNDD showed significant associations with impairment on visuospatial/executive, attention, and language MoCA subtests, after allowing for the influence of covariates. PRSNDD and PRSADHD, but not PRSASD, were significantly associated with worse performance on the total MoCA score. Moreover, in the network analysis, the relationships between PRSs for NDD and cognitive impairment were highly interconnected with premorbid variables and PRSs for schizophrenia and educational attainment. Conclusions: These results provide evidence for a possible direct genetic effect on cognitive performance for the PRS of common genetic variations related to neurodevelopment and attention deficit hyperactivity disorder in patients with FEP., This study was funded by the Government of Navarra (grants 17/31 and 18/41) and the Carlos III Health Institute (FEDER Funds) from the Spanish Ministry of Economy and Competitiveness (PI16/02148, PI19/01698, RD21/0009/0025 and RD24/0003/0015). SP was supported by the Psych-STRATA project from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057454.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: a network analysis approach

  • Gil Berrozpe, Gustavo José
  • Segura, Àlex G.
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Giné-Servén, Eloi
  • Vieta, Eduard
  • Mezquida, Gisela
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Roldán, Alexandra
  • Forte, María Florencia
  • Castro, Josefina
  • Bergé, Daniel
  • Rodríguez, Natalia
  • Ballesteros, Alejandro
  • Mas, Sergi
  • Cuesta, Manuel J.
  • Bernardo, Miguel
  • PEPs Group
Psychopathological manifestations and cognitive impairments are core features of psychotic disorders. Polygenic risk scores (PRS) offer insights into the relationships between genetic vulnerability, symptomatology, and cognitive impairments. This study used a network analysis to explore the connections between PRS, cognition, psychopathology, and overall functional outcomes in individuals experiencing a first episode of psychosis (FEP). The study sample comprised 132 patients with FEP. Genetic data were used to construct PRS for mental disorders and cognitive traits via PRS-continuous shrinkage. We conducted comprehensive clinical and neuropsychological assessments at 2 months post-diagnosis and again at a 2-year follow-up. A network analysis was performed to generate two distinct networks and their centrality indices, encompassing 19 variables across domains such as symptoms, cognition, functioning, and PRS. Variables were grouped within related domains, and stronger relationships were observed within domains than between them. PRS for schizophrenia showed weak negative associations with attention, working memory, and verbal memory, while PRS for cognitive performance showed weak positive associations with attention. Negative symptoms were negatively associated with functioning and verbal memory at both the 2-month and 2-year assessments, as well as with social cognition at 2 years. Poor functioning was moderately related to greater severity of Positive and Negative Syndrome Scale dimensions. This study identified pathways linking PRS, cognition, symptoms, and functioning, suggesting that genetic risk may serve as a marker of vulnerability and disorder progression. The findings also highlight the importance of considering genetic predispositions alongside clinical and cognitive factors to better understand the heterogeneity of psychotic disorders., EV thanks the support of the Spanish Ministry of Science and Innovation (PI21/00787) integrated into the Plan Nacional de I + D + I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2021-SGR-01358), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project).